Evidence map›Paper›PMID 36943035›Full record

ArticleeLife2023

Impact of COVID-19 pandemic on breast and cervical cancer screening in Denmark: A register-based study.

Mette Hartmann Nonboe, George Napolitano, Jeppe Bennekou Schroll, Ilse Vejborg, Marianne Waldstrøm, Elsebeth Lynge

Open access · goldFull text read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Global determinants of gynecologic cancer incidence and mortality: A cluster-based analysis with predictive insights.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Article
  2. Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Mette Hartmann NonboeCenter for Epidemiological Research, Nykøbing Falster Hospital, Nykøbing Falster, Denmark.ORCID 0000-0003-0085-9109
George NapolitanoDepartment of Public Health, University of Copenhagen, Copenhagen, Denmark.
Jeppe Bennekou SchrollDepartment of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.
Ilse VejborgDepartment of Breast Examinations, Copenhagen University Hospital Herlev/Gentofte, Copenhagen, Denmark.
Marianne WaldstrømDepartment of Pathology, Aarhus University Hospital, Aarhus N, Denmark.
Elsebeth LyngeCenter for Epidemiological Research, Nykøbing Falster Hospital, Nykøbing Falster, Denmark.
Sjællands Universitetshospital, Nykøbing F. · DKAarhus University Hospital · DKCopenhagen University Hospital · DKOdense University Hospital · DKUniversity of Copenhagen · DK

Funding

Region Zealand R22-A597
6 · The paper itself

Abstract

Background: Denmark was one of the few countries where it was politically decided to continue cancer screening during the COVID-19 pandemic. We assessed the actual population uptake of mammography and cervical screening during this period. Methods: The first COVID-19 lockdown in Denmark was announced on 11 March 2020. To investigate possible changes in cancer screening activity due to the COVID-19 pandemic, we analysed data from the beginning of 2017 until the end of 2021. A time series analysis was carried out to discover possible trends and outliers in the screening activities in the period 2017-2021. Data on mammography screening and cervical screening were retrieved from governmental pandemic-specific monitoring of health care activities. Results: A brief drop was seen in screening activity right after the first COVID-19 lockdown, but the activity quickly returned to its previous level. A short-term deficit of 43% [CI -49 to -37] was found for mammography screening. A short-term deficit of 62% [CI -65 to -58] was found for cervical screening. Furthermore, a slight, statistically significant downward trend in cervical screening from 2018 to 2021 was probably unrelated to the pandemic. Other changes, for example, a marked drop in mammography screening towards the end of 2021, also seem unrelated to the pandemic. Conclusions: Denmark continued cancer screening during the pandemic, but following the first lockdown a temporary drop was seen in breast and cervical screening activity. Funding: Region Zealand (R22-A597).

Indexed as

Breast NeoplasmsCOVID-19Uterine Cervical NeoplasmsCommunicable Disease ControlDenmarkEarly Detection of CancerFemaleHumansPandemicsbreast cancer screeningcancer screeningcervical cancer screeningCOVID-19epidemiologyglobal healthhumantime trend analysis

Identifiers

PMID36943035
PMCPMC10030107
OpenAlexW4328048855

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read59
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.